GSK Sues Apotex to Protect Enlarged Prostate Drug Avodart

Washington Drug Letter
GlaxoSmithKline (GSK) is suing Apotex, saying the generic maker’s proposed version of enlarged prostate drug Avodart would infringe on a GSK patent and should be prohibited from the U.S. market until the patent expires in late 2015.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00